Pennytobuck.com Stock Report On Pwrm,sny- Power 3 Medical Products, Sanofi-aventis

PWRM, Power 3 Medical Products Inc., PWRM.OB

PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

** THE INTERNATIONAL CONGRESS OF ALZHEIMERS DISEASE ACCEPTS FOUR SCIENTIFIC PRESENTATIONS BY PWRM **

Four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimers Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the PWRMs NuroPro AD biomarkers and blood test for Alzheimers disease.

The four studies to be presented involve a total of 154 Alzheimers disease patients and 91 Parkinsons disease patients, as well as 210 age-matched normal control individuals and 173 disease control individuals.

- According to recent estimates, as many as 2.4 million to 4.5 million Americans have Alzheimers disease (AD). Unless the disease can be effectively treated or prevented, the number of people with AD will increase significantly if current population trends continue. Thats because the risk of AD increases with age, and the U.S. population is aging. The number of people age 65 and older is expected to grow from 39 million in 2008 to 72 million in 2030, and the number of people with AD doubles for every 5-year interval beyond age 65. (Source: CLICK HERE)

Furthermore, PWRM recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimers disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer NYSE: PFE), Exelon (Rivastigmine, Novartis NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories NYSE: FRX). These results relate to the genetically distinct groups of Alzheimers disease patients, i.e., those individuals who possess the Alzheimers high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

PWRMs NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimers disease. With these results, PWRMs NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

PWRM has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the worlds most prestigious peer-reviewed scientific journals.

More about PWRM at www.power3medical.com

SNY, Sanofi-Aventis

SNY, a pharmaceutical company, contributes to enhancing life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in the United States and Europe.

SNY and the Juvenile Diabetes Research Foundation (JDRF) reported a unique partnership to develop therapeutic treatments for people with type 1 diabetes at different stages of the disease both those living with the disease and the newly diagnosed as well as preventing diabetes in those at risk.

Toward those goals, the partnership will focus on therapeutics such as immune therapies and beta cell regeneration.

Under the partnership, sanofi-aventis and JDRF will jointly provide academic investigators and non-profit medical research organizations with funding to conduct research projects in regeneration and immune therapy. This partnership will provide sanofi-aventis with options to the intellectual property developed by researchers who receive funding through the program.

More about SNY at en.sanofi-aventis.com

***********************************

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

***********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, I

by: Bill Pennyman

POST COMMENT

Medical debt collection –a stress reliever Why is drug rehab so important? Do I Have A Medical Malpractice Case D-Mannose - An effective medicine in treating urine infection Important Recommendations on Safe Handling of Hazardous Drugs Cultural Indoctrination Prevails Over Medical Science And Common Sense Role Of Interpreters And Translators In Medical Field Random Drug Testing Angry Gerd Drug Users Mount Class Action Lawsuit Help for Medical Bills - The Very Best Methods to Quickly Eliminate Medical Debt The unending benefits of Oregano over medical science Classes Medical Billing - Preparing For Your Exam Teaser Dalak (Massage) in Unani Medicine